Peptron, Inc. (087010.KQ)
KRW 98300.0
(-1.99%)
KRW 98300.0
(-1.99%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.14 Billion KRW | -19.45% |
| 2022 | -1.46 Billion KRW | -212.21% |
| 2021 | 1.3 Billion KRW | 167.91% |
| 2020 | -1.92 Billion KRW | -4.84% |
| 2019 | -1.83 Billion KRW | -241.73% |
| 2018 | 1.29 Billion KRW | 19.9% |
| 2017 | 1.08 Billion KRW | -2.03% |
| 2016 | 1.1 Billion KRW | 36.92% |
| 2015 | 806.25 Million KRW | -26.26% |
| 2014 | 1.09 Billion KRW | -17.85% |
| 2013 | 1.33 Billion KRW | 36.51% |
| 2012 | 974.95 Million KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -587.77 Million KRW | -5.13% |
| 2024 Q1 | -559.09 Million KRW | -75.04% |
| 2023 Q4 | -319.4 Million KRW | 31.61% |
| 2023 Q1 | -455.45 Million KRW | 76.51% |
| 2023 Q3 | -467.04 Million KRW | -10.77% |
| 2023 Q2 | -421.62 Million KRW | 7.43% |
| 2023 FY | -1.75 Billion KRW | -19.45% |
| 2022 Q4 | -1.93 Billion KRW | -307.92% |
| 2022 Q3 | -475.41 Million KRW | -3.76% |
| 2022 Q2 | -458.2 Million KRW | -132.62% |
| 2022 Q1 | 1.4 Billion KRW | 471.55% |
| 2022 FY | -1.46 Billion KRW | -212.21% |
| 2021 Q3 | -615.31 Million KRW | -121.63% |
| 2021 Q1 | -542.49 Million KRW | -299.18% |
| 2021 FY | 1.3 Billion KRW | 167.91% |
| 2021 Q2 | 2.84 Billion KRW | 624.31% |
| 2021 Q4 | -378.06 Million KRW | 38.56% |
| 2020 Q1 | 99.97 Million KRW | -32.24% |
| 2020 FY | -1.92 Billion KRW | -4.84% |
| 2020 Q4 | 272.36 Million KRW | -13.96% |
| 2020 Q3 | 316.55 Million KRW | -1.34% |
| 2020 Q2 | 320.85 Million KRW | 220.94% |
| 2019 Q3 | 108.35 Million KRW | 419.17% |
| 2019 Q2 | 20.87 Million KRW | -92.81% |
| 2019 FY | -1.83 Billion KRW | -241.73% |
| 2019 Q1 | 290.3 Million KRW | -45.35% |
| 2019 Q4 | 147.53 Million KRW | 36.16% |
| 2018 Q1 | 463.11 Million KRW | -0.37% |
| 2018 Q3 | 124.48 Million KRW | -54.33% |
| 2018 FY | 1.29 Billion KRW | 19.9% |
| 2018 Q4 | 531.2 Million KRW | 326.72% |
| 2018 Q2 | 272.56 Million KRW | -41.15% |
| 2017 Q3 | 331.53 Million KRW | 17.26% |
| 2017 Q2 | 282.72 Million KRW | 234.5% |
| 2017 Q1 | 84.52 Million KRW | -80.52% |
| 2017 FY | 1.08 Billion KRW | -2.03% |
| 2017 Q4 | 464.83 Million KRW | 40.21% |
| 2016 Q3 | 193.63 Million KRW | -45.98% |
| 2016 Q1 | 213.17 Million KRW | 105.0% |
| 2016 FY | 1.1 Billion KRW | 36.92% |
| 2016 Q2 | 358.43 Million KRW | 68.14% |
| 2016 Q4 | 433.99 Million KRW | 124.14% |
| 2015 Q3 | 338.54 Million KRW | 498.64% |
| 2015 FY | 806.25 Million KRW | -26.26% |
| 2015 Q4 | 103.99 Million KRW | -69.28% |
| 2015 Q2 | 56.55 Million KRW | -84.9% |
| 2015 Q1 | 374.53 Million KRW | 0.0% |
| 2014 FY | 1.09 Billion KRW | -17.85% |
| 2014 Q2 | 318.23 Million KRW | 217.59% |
| 2014 Q1 | 100.2 Million KRW | 0.0% |
| 2014 Q3 | 486.05 Million KRW | 52.74% |
| 2013 FY | 1.33 Billion KRW | 36.51% |
| 2012 FY | 974.95 Million KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Co., Ltd. | -6.01 Billion KRW | 118.97% |
| iNtRON Biotechnology, Inc. | 4.56 Billion KRW | 74.992% |
| BINEX Co., Ltd. | 56.65 Billion KRW | 97.987% |
| Bioneer Corporation | 199.25 Billion KRW | 99.428% |
| Anterogen.Co.,Ltd. | 2.21 Billion KRW | 48.47% |
| MEDIPOST Co., Ltd. | 40.18 Billion KRW | 97.162% |
| CrystalGenomics, Inc. | 1.45 Billion KRW | 21.718% |
| Helixmith Co., Ltd | 2.12 Billion KRW | 46.246% |
| Chabiotech Co.,Ltd. | 255.19 Billion KRW | 99.553% |
| Medy-Tox Inc. | 128.16 Billion KRW | 99.11% |
| Amicogen, Inc. | 51.51 Billion KRW | 97.786% |
| Genexine, Inc. | 387.48 Million KRW | -194.355% |
| HLB Therapeutics Co.,Ltd. | 6.69 Billion KRW | 82.962% |
| LegoChem Biosciences, Inc. | 17.79 Billion KRW | 93.591% |
| ALTEOGEN Inc. | 31.19 Billion KRW | 96.344% |
| PharmaResearch Co., Ltd. | 182.25 Billion KRW | 99.374% |
| SillaJen, Inc. | 1.45 Billion KRW | 21.703% |
| JETEMA, Co., Ltd. | 26.58 Billion KRW | 95.709% |
| OliX Pharmaceuticals,Inc | 14.42 Billion KRW | 92.092% |
| Genomictree Inc. | -1.03 Billion KRW | 209.82% |
| MedPacto, Inc. | -1.83 Billion KRW | 162.236% |
| D&D Pharmatech | 18.67 Billion KRW | 93.893% |
| EASY BIO,Inc. | 50.88 Billion KRW | 97.759% |
| GI Innovation, Inc. | 1.98 Billion KRW | 42.668% |